outcomes of autosct, allosct & car-t cell therapy in patients with tp53-altered mcl
Published 11 months ago • 261 plays • Length 2:48Download video MP4
Download video MP3
Similar videos
-
1:49
car-t cell approaches in cll: current progress & future directions
-
1:58
patient-reported outcomes vs performance-based metrics: the effects of car-t therapy on cognition
-
2:05
the cost-effectiveness of car t-cell therapy
-
4:39
intermittent neutrophil recovery associated with improved car-t outcomes in r/r lbcl
-
3:21
patient-reported outcomes with car t-cell therapy
-
4:21
mrd as a monitoring technique of allosct and car-t in aml/all
-
1:02
the use of car-t cell products in a real-world setting
-
4:24
investigating production failure and out-of-specification production of car t-cell therapeutics
-
2:11
improving treatment outcomes of car t-cell therapy
-
0:52
the future of car t-cell therapy for aml
-
2:14
exploring the potential role of cd7-targeting car-t cells for the treatment of t-all
-
1:39
the role of myeloid cells in car-t cell therapy
-
0:50
improving car-t cell efficacy: optimizing car constructs and counteracting tumor escape
-
3:47
update on the guidelines for the diagnosis, grading & management of icaht following car-t therapy
-
1:27
car t-cells in all: an overview
-
8:16
future avenues for car t-cell therapy in all
-
1:08
point-of-care car t-cells
-
1:28
assessment of car-t and tcr adverse events
-
1:56
the state of car t-cell products today